Introduction
============

In the US, there are now four approved ALK inhibitors for patients with metastatic *ALK*-rearranged lung cancer and many more at various development stages. Because of significant clinical benefits these ALK inhibitors provide, it is imperative for clinicians to screen appropriate patients for this driver mutation with a molecular testing platform capable of capturing all *ALK* fusions. For patients who progress on an ALK inhibitor, performing repeat biopsy to look for mechanism(s) of resistance is highly recommended. Identifying an ALK resistance mutation may guide selection of another ALK inhibitor with known activity against the specific mutation. Here, we report a novel *VKORC1L1-ALK* fusion with an acquired ALK T1151K resistance mutation detected in a patient who had disease progression after being on crizotinib for over 8 years. He had a dramatic response to alectinib illustrated in the following narrative indicating that T1151K confers sensitivity to alectinib.

Case presentation
=================

A 54-year-old Caucasian man, former smoker of \<5 pack years, originally underwent resection for locally advanced adenocarcinoma of the lung in April 2006 followed by adjuvant chemoradiation with weekly carboplatin/paclitaxel for focally positive margin. He was found to have metastatic disease in his pelvis in November 2008 for which he received palliative radiation. In October 2009, a computed tomography (CT) scan performed for cough showed multiple bilateral subcentimeter lung nodules and a large left pleural effusion. However, the patient had elected not to receive any treatment until February 2010 when he presented to our cancer center to discuss participation in clinical trial. The molecular profiling performed at the Massachusetts General Hospital revealed an *ALK* rearrangement, so he was enrolled in the PROFILE 1001 study (NCT00585195) in March 2010. He had a sustained partial response (PR, −27% by RECIST 1.1) to crizotinib at 250 mg twice daily confirmed by a contrast CT scan in October 2012. He declined further scans afterwards, and so he was switched to commercial supply of crizotinib in February 2013.

In April 2018, the patient developed dry cough while on crizotinib for which a contrast CT scan of the chest was performed that showed complete opacification of the left hemithorax ([Figure 1](#f1-lctt-9-111){ref-type="fig"}). Restaging scans confirmed disease progression in both lungs, thoracic lymph nodes, pleura, and bone. He was immediately switched to alectinib at 600 mg twice daily while comprehensive genomic profiling (CGP) via Foundation Medicine, Inc. (Cambridge, MA, USA) was performed on a plasma-based liquid biopsy which subsequently identified a novel *VKORC1L1-ALK* fusion as well as an ALK T1151K resistance mutation. This CGP assay covers 62 genes to ×5,000 unique coverage and includes intron baiting for rearrangements of six genes (*ALK*, *EGFR*, *FGFR3*, *PDGFR*-α, *ROS1*, and *RET*). Alectinib was continued based on predicted efficacy of this ALK inhibitor against T1151K. A follow-up contrast CT scan of the chest 14 weeks later showed a dramatic response (--76% by RECIST 1.1) including resolution of a 2.9 cm left paravertebral mass at T1--2 level, decrease in size of the right pulmonary nodule from 1.8 to 1.1 cm, and significant improvement of the left lung aeration ([Figure 1](#f1-lctt-9-111){ref-type="fig"}). Of note, prior to this follow-up scan, the patient underwent endobronchial cryosurgery for tissue extraction and spray cryotherapy of an endobronchial mass in order to prevent any significant pulmonary hemorrhage and for airway recanalization, but we did not obtain enough tissue for CGP. At the time of this manuscript preparation, the patient has been on alectinib for over 23 weeks with no reported symptoms. A written informed consent was obtained to have the case details published, and institutional approval was not required to publish this case report.

Discussion
==========

We believe this is the first report of *VKORC1L1-ALK* fusion detected in a lung cancer patient. Ever since the discovery of the transforming *EML4-ALK* fusion gene by Soda and Rikova et al in 2007, various *ALK* fusion partners have been identified including *TFG*, *KIF5B*, *KCL1*, *PTPN3*, *STRN*, *HIP1*, *TPR*, *BIRC6*, *DCTN1*, *SQSTM1*, *SOCS5*, *CLIP4*, *CLTC*, *PRKAR1A*, *PPM1B*, *EIF2AK3*, *CRIM1*, *GCC2*, *DYSF*, *ITGAV*, *VIT*, *PLEKHA7*, and *CUX1*.[@b1-lctt-9-111]--[@b19-lctt-9-111] A list of chronologically published fusion partners in *ALK*-rearranged lung cancer with references is summarized in [Table 1](#t1-lctt-9-111){ref-type="table"}. The *VKORC1L1* gene encodes an enzyme known as vitamin K 2,3-epoxide reductase, whose catalytic function is critical for the vitamin K cycle. The vitamin K-dependent proteins have various physiological roles that are not just restricted to coagulation and hemostasis. Although little is known of the functions of these proteins in direct tumorigenesis, they may contribute to remodeling of tumor microenvironment as vascular endothelial cell survival depends on vitamin K. In addition, the mRNA and protein expressions of VKORC1L1 in lung have been reported.[@b20-lctt-9-111] The *VKORC1L1* gene is located on chromosome 7q11.21 and only contains three exons with 531 nucleotides. The encoded protein product has 176 amino acids (aa) with four endoplasmic reticulum transmembrane domains. In this case, exon 1 of *VKORC1L1* (aa 1--64) was fused with exons 20--29 (aa 1058--1620) of the *ALK* gene generating the final fusion protein which contains the full ALK tyrosine kinase domain (aa 1116--1329) ([Figure 2](#f2-lctt-9-111){ref-type="fig"}). Interestingly, our patient's tumor was found to harbor *ALK* rearrangement in 2010, but the specific fusion partner could not be identified by fluorescence in situ hybridization at the time.

The other significance of this report is the demonstration of the sensitivity of the ALK T1151K resistance mutation to alectinib in a clinical patient case. The identification of T1151K as a resistance mutation to crizotinib was reported in 2011 by Zhang et al through an accelerated mutagenesis screen.[@b21-lctt-9-111] Our group was the first to report this resistance mutation in an *ALK*-rearranged lung cancer patient with prior exposure to crizotinib and ceritinib. Based on co-crystal structures of ceritinib/ALK, alectinib/ALK, and lorlatinib/ALK, we concluded that T1151K confers resistance to ceritinib which may be rescued by alectinib or lorlatinib. We also speculated that brigatinib may not be able to completely overcome the T1151K/M resistance mutations according to an in vitro assay as well as the strong interaction of brigatinib with the P-loop of the ALK protein which may be interrupted by the T1151 mutation leading to drug resistance.[@b22-lctt-9-111] The patient described in our previous case report has been on lorlatinib for over two years with a PR (--32% by RECIST 1.1). The dramatic response seen in this case would require longer follow-up to determine if the response is durable. Interestingly, as alectinib only has weak interaction with the P-loop of the ALK protein while lorlatinib has moderate interaction, alectinib may be more potent than lorlatinib to rescue patients with tumors harboring the ALK T1151K resistance mutation, which could explain a greater response seen in this patient treated with alectinib.

One limitation of this case report is that from a molecular standpoint it remains unclear how the ALK protein is activated by its fusion partner VKORC1L1 as this protein product does not appear to contain a dimerization domain similar to EML4. It would be ideal to demonstrate positive ALK immunohistochemistry or the final VKORC1L1-ALK fusion protein and phospho-ALK by Western blot for instance. However, our patient declined tissue biopsy and his therapeutic bronchoscopy did not yield enough tissue to perform such laboratory assays. It is fortunate that liquid biopsy revealed this novel *ALK* fusion and an acquired ALK resistance mutation. More importantly, the dramatic response seen in follow-up scans highly suggests that his disease process remains dependent on the ALK signaling pathway.

The patient will undergo routine CT scans to monitor treatment response as well as surveillance brain magnetic resonance imaging as it is a common site of disease progression for patients with *ALK*-rearranged lung cancer. He does not have any brain metastasis at present. Should his disease progress again, we plan to explore resistance mechanism(s) by repeat biopsy. As patients are exposed to sequential ALK inhibitors, they are more likely to develop compound ALK resistance mutations. This phenomenon has been elegantly illustrated by Yoda et al in their approach to define lorlatinib-resistant ALK mutations.[@b23-lctt-9-111] To prevent highly refractory compound mutations from emerging, one might argue for the upfront use of the most potent ALK inhibitor and designing next-generation ALK inhibitors that can overcome these resistance mutations.

Conclusion
==========

*ALK*-rearranged lung cancer defines a distinctive molecular cohort of patients whose outcomes are significantly improved by the availability of ALK inhibitors. Thus, screening for this driver mutation by a comprehensive molecular testing platform is absolutely necessary in routine practice. This is the first case report of a novel *VKORC1L1-ALK* fusion detected in a lung cancer patient. The patient had been on crizotinib for over 8 years until emergence of an ALK T1151K resistance mutation that was successfully treated with alectinib, demonstrating for the first time the activity of alectinib against T1151K in the clinic.
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![Contrast CT scans of the chest showing a left paravertebral mass at T1--2 level (indicated by a red circle) prior to use of alectinib (**A** and **C**) and resolution of this mass 14 weeks after initiating alectinib (**B** and **D**). Contrast CT scans of the chest showing decrease in size of the right pulmonary nodule (indicated by a red arrow) and significant improvement of the left lung aeration (indicated by a red star) 14 weeks after initiating alectinib (**F** and **H**) as compared with prior to use of alectinib (**E** and **G**).\
**Abbreviation:** CT, computed tomography.](lctt-9-111Fig1){#f1-lctt-9-111}

![Schema of the VKORC1L1-ALK fusion protein.\
**Notes:** The *VKORC1L1* gene only contains three exons with 531 nucleotides. The encoded protein product has 176 aa with four endoplasmic reticulum transmembrane domains (aa 17--37, aa 92--112, aa 114--134, and aa 135--155). In this case, exon 1 of *VKORC1L1* (aa 1--64) is fused with exons 20--29 (aa 1058--1620) of the *ALK* gene generating the final fusion protein which contains the full ALK tyrosine kinase domain (aa 1116--1329). Of note, the luminal domain of the VKORC1L1 protein itself contains aa 38--91, but the final VKORC1L1-ALK fusion protein only contains aa 38--64 which is highlighted in yellow. Similarly, the transmembrane domain of the ALK protein itself contains aa 1039--1059, but the final VKORC1L1-ALK fusion protein only contains aa 1058--1059 which is highlighted in brown.\
**Abbreviation:** aa, amino acid.](lctt-9-111Fig2){#f2-lctt-9-111}

###### 

Published fusion partners in *ALK*-rearranged lung cancer

  Number   Fusion partner   Reference(s)
  -------- ---------------- ------------------------------------------------------------------------------------------------------
  1        EML4             Soda et al, *Nature* 2007[@b1-lctt-9-111]; Rikova et al, *Cell* 2007[@b2-lctt-9-111]
  2        TFG              Rikova et al, *Cell* 2007[@b2-lctt-9-111]
  3        KIF5B            Takeuchi et al, *Clin Cancer Res* 2009[@b3-lctt-9-111]
  4        KCL1             Togashi et al, *PLoS One* 2012[@b4-lctt-9-111]
  5        PTPN3            Jung et al, *Genes Chromosomes Cancer* 2012[@b5-lctt-9-111]
  6        STRN             Majewski et al, *J Pathol* 2013[@b6-lctt-9-111]
  7        HIP1             Fang et al, *J Thorac Oncol* 2014[@b7-lctt-9-111]; Hong et al, *J Thorac Oncol* 2014[@b8-lctt-9-111]
  8        TPR              Choi et al, *J Thorac Oncol* 2014[@b9-lctt-9-111]
  9        BIRC6            Shan et al, *J Thorac Oncol* 2015[@b10-lctt-9-111]
  10       DCTN1            Iyevleva et al, *Cancer Lett* 2015[@b11-lctt-9-111]
  11       SQSTM1           Iyevleva et al, *Cancer Lett* 2015[@b11-lctt-9-111]
  12       SOCS5            Drilon et al, *Clin Cancer Res* 2015[@b12-lctt-9-111]
  13       CLIP4            Drilon et al, *Clin Cancer Res* 2015[@b12-lctt-9-111]
  14       CLTC             Ali et al, *Oncologist* 2016[@b13-lctt-9-111]
  15       PRKAR1A          Ali et al, *Oncologist* 2016[@b13-lctt-9-111]
  16       PPM1B            Ali et al, *Oncologist* 2016[@b13-lctt-9-111]
  17       EIF2AK3          Ali et al, *Oncologist* 2016[@b13-lctt-9-111]
  18       CRIM1            Tan et al, *J Clin Oncol* 2016[@b14-lctt-9-111]
  19       GCC2             Jiang et al, *Lung Cancer* 2018[@b15-lctt-9-111]
  20       DYSF             Yin et al, *J Thorac Oncol* 2018[@b16-lctt-9-111]
  21       ITGAV            Yin et al, *J Thorac Oncol* 2018[@b16-lctt-9-111]
  22       VIT              Hu et al, *J Thorac Oncol* 2018[@b17-lctt-9-111]
  23       PLEKHA7          Schrock et al, *J Thorac Oncol* 2018[@b18-lctt-9-111]
  24       CUX1             Zhang et al, *J Thorac Oncol* 2018[@b19-lctt-9-111]
  25       VKORC1L1         This case[\*](#tfn1-lctt-9-111){ref-type="table-fn"}

**Notes:**

This fusion partner was detected in conjunction with an acquired ALK resistance mutation.
